Akkermansia muciniphila improves chronic colitis‐induced enteric neuroinflammation in mice

Abstract

AbstractBackgroundInflammatory bowel diseases (IBD) are chronic diseases that are not fully understood. Drugs in use can only be applied for a short time due to their side effects. Therefore, research is needed to develop new treatment approaches. In addition, it has been proven that IBD causes degeneration in the enteric nervous system (ENS). In recent years, it has been discussed that probiotics may have positive effects in the prevention and treatment of inflammatory enteric degeneration. Akkermansia muciniphila (A. muciniphila) is an anaerobic bacterium found in the mucin layer of the intestinal microbiota. It has been found that the population of A. muciniphila decreases in the case of different diseases. In light of this information, the curative effect of A. muciniphila application on colitis‐induced inflammation and enteric degeneration was investigated.MethodsIn this study, 5 weeks of A. muciniphila treatment in Trinitro‐benzene‐sulfonic acid (TNBS)–induced chronic colitis model was investigated. Colon samples were examined at microscopic, biochemical, and molecular levels. Fecal samples were collected before, during, and after treatment to evaluate the population changes in the microbiota. Specific proteins secreted from the ENS were evaluated, and enteric degeneration was examined.ResultsAs a result of the research, the ameliorative effects of A. muciniphila were shown in the TNBS colitis model‐induced inflammation and ENS damage.DiscussionIn light of these results, A. muciniphila can potentially be evaluated as a microbiome‐based treatment for IBD with further clinical and experimental studies.